Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition von Thibault, Benoît, Castells, Magali, Delord, Jean-Pierre, Couderc, Bettina

Volltext

Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death von Castells, Magali, Thibault, Benoît, Delord, Jean-Pierre, Couderc, Bettina

Volltext

Vinflunine: A New Microtubule Inhibitor Agent von Bennouna, Jaafar, Delord, Jean-Pierre, Campone, Mario, Nguyen, Laurent

Volltext

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study von Chung, Hyun Cheol, Ros, Willeke, Delord, Jean-Pierre, Perets, Ruth, Italiano, Antoine, Shapira-Frommer, Ronnie, Manzuk, Lyudmila, Piha-Paul, Sarina A, Xu, Lei, Zeigenfuss, Susan, Pruitt, Scott K, Leary, Alexandra

Volltext

Acute skin reaction suggestive of pembrolizumab-induced radiosensitization von Sibaud, Vincent, David, Isabelle, Lamant, Laurence, Resseguier, Sarah, Radut, Roxana, Attal, Justine, Meyer, Nicolas, Delord, Jean-Pierre

Volltext

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF -Mutant Melanoma von Delord, Jean-Pierre, Robert, Caroline, Nyakas, Marta, McArthur, Grant A, Kudchakar, Ragini, Mahipal, Amit, Yamada, Yasuhide, Sullivan, Ryan, Arance, Ana, Kefford, Richard F, Carlino, Matteo S, Hidalgo, Manuel, Gomez-Roca, Carlos, Michel, Daniela, Seroutou, Abdelkader, Aslanis, Vassilios, Caponigro, Giordano, Stuart, Darrin D, Moutouh-de Parseval, Laure, Demuth, Tim, Dummer, Reinhard

Volltext

Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628 von Stathis, Anastasios, Zucca, Emanuele, Bekradda, Mohamed, Gomez-Roca, Carlos, Delord, Jean-Pierre, de La Motte Rouge, Thibault, Uro-Coste, Emmanuelle, de Braud, Filippo, Pelosi, Giuseppe, French, Christopher A

Volltext

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study von Strosberg, Jonathan, Mizuno, Nobumasa, Doi, Toshihiko, Grande, Enrique, Delord, Jean-Pierre, Shapira-Frommer, Ronnie, Bergsland, Emily, Shah, Manisha, Fakih, Marwan, Takahashi, Shunji, Piha-Paul, Sarina A, O'Neil, Bert, Thomas, Sajeve, Lolkema, Martijn P, Chen, Menghui, Ibrahim, Nageatte, Norwood, Kevin, Hadoux, Julien

Volltext

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial von Naumann, R Wendel, Hollebecque, Antoine, Meyer, Tim, Devlin, Michael-John, Oaknin, Ana, Kerger, Joseph, López-Picazo, Jose M, Machiels, Jean-Pascal, Delord, Jean-Pierre, Evans, Thomas R J, Boni, Valentina, Calvo, Emiliano, Topalian, Suzanne L, Chen, Tian, Soumaoro, Ibrahima, Li, Bin, Gu, Junchen, Zwirtes, Ricardo, Moore, Kathleen N

Volltext

PD-1 Blockade in Anaplastic Thyroid Carcinoma von Capdevila, Jaume, Wirth, Lori J, Ernst, Thomas, Ponce Aix, Santiago, Lin, Chia-Chi, Ramlau, Rodryg, Butler, Marcus O, Delord, Jean-Pierre, Gelderblom, Hans, Ascierto, Paolo A, Fasolo, Angelica, Führer, Dagmar, Hütter-Krönke, Marie Luise, Forde, Patrick M, Wrona, Anna, Santoro, Armando, Sadow, Peter M, Szpakowski, Sebastian, Wu, Hongqian, Bostel, Geraldine, Faris, Jason, Cameron, Scott, Varga, Andreea, Taylor, Matthew

Volltext

Improving patient selection for immuno‐oncology phase 1 trials: External validation of six prognostic scores in a French Cancer Center von Al Darazi, Ghassan, Martin, Elodie, Delord, Jean‐Pierre, Korakis, Iphigenia, Betrian, Sarah, Estrabaut, Myriam, Poublanc, Muriel, Gomez‐Roca, Carlos, Filleron, Thomas

Volltext

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer von Rugo, Hope S, Delord, Jean-Pierre, Im, Seock-Ah, Ott, Patrick A, Piha-Paul, Sarina A, Bedard, Philippe L, Sachdev, Jasgit, Le Tourneau, Christophe, van Brummelen, Emilie M J, Varga, Andrea, Salgado, Roberto, Loi, Sherene, Saraf, Sanatan, Pietrangelo, Dina, Karantza, Vassiliki, Tan, Antoinette R

Volltext

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, c... von Le Tourneau, Christophe, Dr, Delord, Jean-Pierre, Prof, Gonçalves, Anthony, Prof, Gavoille, Céline, MD, Dubot, Coraline, MD, Isambert, Nicolas, MD, Campone, Mario, Prof, Trédan, Olivier, MD, Massiani, Marie-Ange, MD, Mauborgne, Cécile, MSc, Armanet, Sebastien, MSc, Servant, Nicolas, PhD, Bièche, Ivan, PhD, Bernard, Virginie, PhD, Gentien, David, PhD, Jezequel, Pascal, MD, Attignon, Valéry, PhD, Boyault, Sandrine, PhD, Vincent-Salomon, Anne, MD, Servois, Vincent, MD, Sablin, Marie-Paule, MD, Kamal, Maud, PhD, Paoletti, Xavier, PhD

Volltext

Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin von Hassan, Raffit, Alewine, Christine, Mian, Idrees, Spreafico, Anna, Siu, Lillian L., Gomez‐Roca, Carlos, Delord, Jean‐Pierre, Italiano, Antoine, Lassen, Ulrik, Soria, Jean‐Charles, Bahleda, Rastilav, Thomas, Anish, Steinberg, Seth M., Peer, Cody J., Figg, William D., Niederfellner, Gerhard, Méresse Naegelen, Valérie, Pastan, Ira

Volltext

Emerging new anticancer therapies in 2013 von Gomez-Roca, Carlos, Delord, Jean-Pierre

Volltext

Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103) von Garralda, Elena, Oh, Do Youn, Italiano, Antoine, Bedard, Philippe L., Delord, Jean‐Pierre, Calvo, Emiliano, LoRusso, Patricia, Wainberg, Zev, Cervantes, Andres, Rodriguez‐Vida, Alejo, Shemesh, Colby S., Sane, Rucha, Mendus, Diana, Ding, Hao, Hendricks, Robert, Meng, Ray, Cho, Byoung Chul, Kim, Tae Won, Wu, Benjamin

Volltext

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study von Cassier, Philippe A, MD, Italiano, Antoine, Dr, Gomez-Roca, Carlos A, MD, Le Tourneau, Christophe, MD, Toulmonde, Maud, MD, Cannarile, Michael A, PhD, Ries, Carola, PhD, Brillouet, Anne, BSc, Müller, Claudia, PhD, Jegg, Anna-Maria, PhD, Bröske, Ann-Marie, PhD, Dembowski, Markus, PhD, Bray-French, Katharine, PhD, Freilinger, Christine, PhD, Meneses-Lorente, Georgina, PhD, Baehner, Monika, PhD, Harding, Ross, PhD, Ratnayake, Jayantha, PhD, Abiraj, Keelara, PhD, Gass, Nathalie, PhD, Noh, Karen, PharmD, Christen, Randolph D, MD, Ukarma, Lidia, MD, Bompas, Emmanuelle, MD, Delord, Jean-Pierre, Prof, Blay, Jean-Yves, Prof, Rüttinger, Dominik, MD

Volltext

Development of Photoonycholysis with Vandetanib Therapy von Negulescu, Miruna, Zerdoud, Slimane, Boulinguez, Serge, Tournier, Emilie, Delord, Jean-Pierre, Baran, Robert, Sibaud, Vincent

Volltext

Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies von Sibaud, Vincent, Meyer, Nicolas, Lamant, Laurence, Vigarios, Emmanuelle, Mazieres, Julien, Delord, Jean Pierre

Volltext

A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO p... von Gravis, Gwenaelle, Marino, Patricia, Olive, Daniel, Penault-LLorca, Frederique, Delord, Jean-Pierre, Simon, Clotilde, Lamrani-Ghaouti, Assia, Sabatier, Renaud, Ciccolini, Joseph, Boher, Jean-Marie

Volltext